Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China

Senti Biosciences, Inc.

First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.
SN301A is SENTI-301A CAR-NK product candidate manufactured and developed by Celest Therapeutics.
Open-label, single-center study (NCT06652243) evaluating safety, pharmacokinetics, and anti-tumor activity.
Three dose levels administered in 28-day cycles with lymphodepletion conditioning.
Over 40% of global HCC cases occur in China; Senti retains rights outside Greater China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.